G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer
Jenna RobinsoniD, Gem FlintiD, Ian GarneriD, Silvia GalliiD, Thomas E. MaheriD, Marina K. KuimovaiD, Ramón VilariD, Iain A. McNeishiD, Robert Eldon BrowniD, Hector C. KeuniD, Marco Di AntonioiD
Abstract
Epigenetic evolution is a common mechanism used by cancer cells to evade the therapeutic effects of drug treatment. In ovarian cancers, epigenetically-driven resistance may be responsible for a large number of late-stage patient deaths. Here, we describe the first investigation into the role of G-quadruplex (G4) DNA secondary structures in mediating epigenetic regulation in drug-resistant ovarian cancer cells. Through genome-wide mapping of G4s in paired drug-sensitive and drug-resistant cell lines, we find that increased G4 formation is associated with significant increase in gene expression, with high enrichment in signalling pathways previously established to promote drug-resistant states. However, in contrast to previous studies, the expression-enhancing effects of G4s were not found at gene promoters, but intergenic and intronic regions, indicating that G4s promote long-range transcriptional regulation in drug-resistant cells. Furthermore, we discovered that clusters of G4s (super-G4s) are associated with particularly high levels of transcriptional enhancement that surpass the effects of super-enhancers, which act as well established regulatory sites in many cancers. Finally, we demonstrate that targeting G4s with small molecules results in significant down-regulation of pathways associated with drug-resistance, which results in resensitisation of resistant cells to chemotherapy agents. These findings indicate that G4 structures are critical for the epigenetic regulatory networks of drug-resistant cells and may represent a promising target to treat drug-tolerant ovarian cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 22
- FWCI
- 5.03
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- NFATC4 Promotes Quiescence and Chemotherapy Resistance in Ovarian Cancer
A. J. Cole, M. Iyengar, … R. J. Buckanovich·bioRxiv·Jan 11, 2020
- The significance of microRNA genes expression in ovarian cancer cell lines resistant to cytotoxic drugs
D. Kazmierczak, K. Jopek, … R. Januchowski·bioRxiv·Dec 4, 2019
- Design of combination therapeutics from protein response to drugs in ovarian cancer cells
Alexandra Franz, Ciyue Shen, … Chris Sander·bioRxiv·Apr 28, 2025
- Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.
Fabian R. Villagómez, Julie Lang, … Benjamin Guy Bitler·Cancer Research CommunicationsPeer-reviewed·Dec 3, 2024
- G-quadruplex Structures in Dysregulated Long Non-Coding RNA of Ovarian Cancer and their Binding Interactions with Human Serum Albumin
Deepshikha Singh, Chinmayee Shukla, Bhaskar Datta·ACS OmegaPeer-reviewed·Jun 11, 2025
- Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance
J. Gallon, E. Loomis, … J. M. Flanagan·bioRxiv·Feb 24, 2021